FY2030 Earnings Forecast for GPCR Issued By HC Wainwright

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued on Wednesday, February 11th. HC Wainwright analyst A. Ghosh expects that the company will post earnings of ($1.74) per share for the year. HC Wainwright has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share.

Several other equities research analysts have also issued reports on the stock. Stifel Nicolaus lifted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Guggenheim raised their price objective on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Morgan Stanley lifted their price objective on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, Citizens Jmp raised their price target on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a research report on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.45.

Structure Therapeutics Trading Down 5.2%

Shares of GPCR opened at $72.04 on Friday. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90. The company has a market cap of $4.37 billion, a PE ratio of -59.05 and a beta of -2.06. The stock has a 50-day moving average price of $74.30 and a 200-day moving average price of $42.69.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. State of Wyoming purchased a new stake in Structure Therapeutics during the second quarter valued at about $28,000. EverSource Wealth Advisors LLC boosted its holdings in Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after acquiring an additional 901 shares during the period. CWM LLC boosted its holdings in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the period. Assetmark Inc. grew its position in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after acquiring an additional 820 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after purchasing an additional 994 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.